True understanding of disease mechanisms is the key to uncovering novel targets for intervention. TNO’s unique approach combines our expertise with proven technologies – including data mining, system biology and AI algorithms – and (pre)clinical expression data to accurately map human disease networks and weigh pathological pathways. Target candidates are then validated with in vitro strategies, including gene knock-outs and interventions. This discovery workflow was validated using MASH (pdf) (formerly NASH)/liver fibrosis, in which we identified multiple targets that attenuate fibrosis. TNO is now ready to work with partners to both further develop the identified MASH targets and to use our target discovery workflow to map other disease networks and therapeutic indications.